Vistagen Therapeutics (VTGN) FCF Margin (2011 - 2026)
Vistagen Therapeutics (VTGN) posted FCF Margin of 3483.87% for Q1 2026, up 40.49% sequentially from 5854.13% in Q4 2025, and down 6987720.0% YoY from N/an in Q1 2025.
Vistagen Therapeutics (VTGN) FCF Margin (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported FCF Margin for 10 years, with the latest figure at 3483.87% in Q1 2026.
- Quarterly FCF Margin fell 6987720.0% year-over-year to 3483.87% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5240.24% (up 342170.0% YoY) and the FY2026 annual result came in at 5232.47%, up 342947.0% from the prior year.
- FCF Margin rose to 3483.87% in Q1 2026 per VTGN's latest filing, from 5854.13% in the prior quarter.
- Over five years, FCF Margin peaked at 66393.33% in Q1 2025 and troughed at 39456.92% in Q1 2022.
- A 5-year average of 2738.07% and a median of 4546.36% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2025 and 2026: FCF Margin surged 6994460 bps in 2025, then slumped 6987720 bps in 2026.
- Over 5 years, FCF Margin stood at 5407.67% in 2022, then surged by 79 bps to 1159.37% in 2023, then sank by 283 bps to 4437.18% in 2024, then sank by 32 bps to 5854.13% in 2025, then jumped by 40 bps to 3483.87% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 3483.87%, 5854.13%, and 5328.68% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Vistagen Therapeutics | 10.35 Mn | 10.35 Mn | - | -996.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,483.87% |
| Dec 31, 2025 | -5,854.13% |
| Sep 30, 2025 | -5,328.68% |
| Jun 30, 2025 | -7,731.56% |
| Mar 31, 2025 | 66,393.33% |
| Dec 31, 2024 | -4,437.18% |
| Sep 30, 2024 | -5,907.65% |
| Jun 30, 2024 | -13,028.57% |
| Mar 31, 2024 | -3,551.27% |
| Dec 31, 2023 | -1,159.37% |
| Sep 30, 2023 | -2,063.33% |
| Jun 30, 2023 | -3,945.50% |
| Mar 31, 2023 | -4,546.36% |
| Dec 31, 2022 | -5,407.67% |
| Sep 30, 2022 | -1,832.61% |
| Jun 30, 2022 | -5,205.87% |
| Mar 31, 2022 | -39,456.92% |
| Dec 31, 2021 | -3,364.64% |
| Sep 30, 2021 | -4,978.46% |
| Jun 30, 2021 | -1,786.10% |